“Our technology is a game changer in surgical efficiency. Traditional methods require removing the initial diagnostic electrodes, sending the patient home, then bringing them back for a separate laser surgery, which necessitates drilling new holes in the skull. This not only doubles the invasiveness but also lacks diagnostic feedback, post-ablation. Our electrodes stay in place for both diagnosis and treatment, which means after ablation a surgeon can immediately reconnect the electrodes to diagnostic tools to verify the success of the procedure. And — since the electrodes are still in place — any necessary touch-up work can be performed right there and then. This could potentially eliminate the need for additional surgeries, reduce patient risk, and ensure a more precise outcome. Within the next six months, we expect to announce collaborations with pharmaceutical companies for clinical studies using our devices. As a result, our revenue should see a considerable boost as we begin to capitalize on ablation procedures, adding to our existing diagnostic revenue. Additionally, we’re planning to submit for FDA approval new ablation applications in other parts of the body, which could further expand our revenue streams.”
Pharma’s Almanac, Company President and Chief Executive Officer, Dave Rosa